Stuart Poulton - 02 Mar 2026 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton
Issuer symbol
KPTI
Transactions as of
02 Mar 2026
Net transactions value
-$47,998
Form type
4
Filing time
03 Mar 2026, 16:17:43 UTC
Previous filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Poulton Stuart EVP, Chief Development Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton 03 Mar 2026 0001942597

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $47,998 -5,101 -5.1% $9.41 94,328 02 Mar 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.